Fortress Biotech, Inc. (FBIO – Free Report) was a big mover last session, as its shares rose over 8% on the day. The move came after the company reported encouraging fourth-quarter and full-year 2016 results. This also led to far more shares changing hands than in a normal session. This continues the recent uptrend for the company as the stock is now up over 37% in the past one-month time frame.
None of the estimates for this stock were revised over the past 30 days. The Zacks Consensus Estimate also remained unchanged over the same time frame. Friday’s price action is encouraging though, so make sure to keep a close watch on this firm in the near future.
Fortress Biotech currently carries a Zacks Rank #3 (Hold).
A better-ranked stock in the Medical – Biomedical and Genetics space is Anthera Pharmaceuticals, Inc. (ANTH – Free Report) , carrying a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Zacks’ 2017 IPO Watch List
Before looking into the stocks mentioned above, you may want to get a head start on potential tech IPOs that are popping up on Zacks’ radar. Imagine being in the first wave of investors to jump on a company with almost unlimited growth potential? This Special Report gives you the current scoop on 5 that may go public at any time.
One has driven from 0 to a $68 billion valuation in 8 years. Four others are a little less obvious but already show jaw-dropping growth. Download this Watch List today for free >>